Resverlogix Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
17
- Stock Symbol
-
RVX
- Investments
-
1
- Share Price
-
$0.05
- (As of Friday Closing)
Resverlogix General Information
Description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Contact Information
Website
www.resverlogix.comCorporate Office
- 4820 Richard Road Southwest
- Suite 300
- Calgary, Alberta T3E 6L1
- Canada
Corporate Office
- 4820 Richard Road Southwest
- Suite 300
- Calgary, Alberta T3E 6L1
- Canada
Resverlogix Timeline
Resverlogix Stock Performance
As of 13-Nov-2026, Resverlogix’s stock price is $0.05. Its current market cap is $18.1M with 344M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.05 | $0.05 | $0.04 - $0.11 | $18.1M | 344M | 30.4K | -$0.03 |
Resverlogix Financials Summary
As of 30-Jun-2026, Resverlogix has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 93,540 | 95,916 | 72,137 | 74,980 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (5,462) | (3,071) | (4,223) | (14,180) |
| Net Income | (10,690) | (7,767) | (7,635) | (16,741) |
| Total Assets | 8,257 | 7,948 | 7,344 | 6,565 |
| Total Debt | 21,148 | 20,798 | 16,470 | 9,910 |
Resverlogix Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Resverlogix Comparisons
Industry
Financing
Details
Resverlogix Competitors (120)
One of Resverlogix’s 120 competitors is Harmony Biosciences Holdings, a Formerly VC-backed company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings | Formerly VC-backed | Plymouth Meeting, PA | ||||
| Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA | ||||
| Akari Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
| RedHill Biopharma | Formerly VC-backed | Raleigh, NC | ||||
| Omeros | Formerly VC-backed | Seattle, WA |
Resverlogix Patents
Resverlogix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021368618-A1 | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor | Active | 30-Oct-2020 | ||
| AU-2021368618-A9 | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor | Active | 30-Oct-2020 | ||
| AU-2021368618-B2 | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor | Active | 30-Oct-2020 | ||
| CA-3197706-A1 | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor | Pending | 30-Oct-2020 | ||
| EP-4236955-A1 | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor | Pending | 30-Oct-2020 | A61K31/517 |
Resverlogix Signals
Resverlogix Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Resverlogix Investments (1)
Resverlogix’s most recent deal was a Early Stage VC with EOS Technical Holdings for . The deal was made on 04-Jan-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| EOS Technical Holdings | 04-Jan-2024 | Early Stage VC | Business/Productivity Software |
Resverlogix ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Resverlogix FAQs
-
When was Resverlogix founded?
Resverlogix was founded in 2001.
-
Where is Resverlogix headquartered?
Resverlogix is headquartered in Calgary, Canada.
-
What is the size of Resverlogix?
Resverlogix has 17 total employees.
-
What industry is Resverlogix in?
Resverlogix’s primary industry is Biotechnology.
-
Is Resverlogix a private or public company?
Resverlogix is a Public company.
-
What is Resverlogix’s stock symbol?
The ticker symbol for Resverlogix is RVX.
-
What is the current stock price of Resverlogix?
As of 13-Nov-2026 the stock price of Resverlogix is $0.05.
-
What is the current market cap of Resverlogix?
The current market capitalization of Resverlogix is $18.1M.
-
Who are Resverlogix’s competitors?
Harmony Biosciences Holdings, Apellis Pharmaceuticals, Akari Therapeutics, RedHill Biopharma, and Omeros are some of the 120 competitors of Resverlogix.
-
What is Resverlogix’s annual earnings per share (EPS)?
Resverlogix’s EPS for 12 months was -$0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process